Edition:
United States

BioInvent International AB (BINV.ST)

BINV.ST on Stockholm Stock Exchange

2.08SEK
29 Jul 2016
Change (% chg)

-0.01kr (-0.48%)
Prev Close
2.09kr
Open
2.09kr
Day's High
2.09kr
Day's Low
2.06kr
Volume
452,998
Avg. Vol
1,030,280
52-wk High
3.93kr
52-wk Low
1.83kr

BINV.ST

Chart for BINV.ST

About

BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403,... (more)
No analyst recommendations are available for BINV.ST.

Overall

Beta: 0.51
Market Cap(Mil.): kr590.89
Shares Outstanding(Mil.): 282.72
Dividend: --
Yield (%): --

Financials

  BINV.ST Industry Sector
P/E (TTM): -- 41.55 39.69
EPS (TTM): -0.34 -- --
ROI: -49.31 -9.57 14.44
ROE: -49.31 -9.91 15.49

BRIEF-BioInvent Q2 net loss widens, reports higher sales

* Says net sales for april-june 2016 amounted to sek 10 (3.7) million.

Jul 26 2016

BRIEF-Bioinvent says director Dharminder Chahal ups stake to 5 pct

* Bioinvent says Bioinvent's board director dharminder chahal increases his shareholding

May 06 2016

BRIEF-BioInvent, Oncurious and NMTRC starts Phase I/IIa study with TB-403

* BioInvent, Oncurious NV and NMTRC initiating Phase I/IIa study with TB-403 for the treatment of medulloblastoma

May 02 2016

BRIEF-Bioinvent says multiple myeloma phase II study of antibody BI-505 ready to start

* Multiple myeloma phase II study of Bioinvent's antibody BI-505 ready to start Source text for Eikon: Further company coverage:

Apr 18 2016

BRIEF-Bioinvent granted European patent for immune-oncology antibody

* Bioinvent is granted a patent in europe for the immune-oncology antibody BI-505

Mar 16 2016

BRIEF-Bioinvent and Oncurious partner with US research consortium

* Bioinvent and Oncurious partner with US research consortium to accelerate phase I/IIa trial of TB-403 Source text for Eikon: Further company coverage:

Mar 15 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Sadif Analytics Prime
$25.00
Provider : Directors Deals Ltd.
$12.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.